Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 2 1Phase 1/2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 13Plasma cell 4Other hematologic neoplasm 3Dermatologic 3Breast 2Sarcoma 1Gastrointestinal 1CNS 1

Conditions

Oligodendroglioma 1Gliosarcoma 1Glioblastoma 1Brain Neoplasms 1Astrocytoma 1

Interventions

Temozolomide 33Radiotherapy 32pembrolizumab 18Cyclophosphamide 18Irinotecan 16Gemcitabine 16Doxorubicin 16Nivolumab 11Docetaxel 11Sirolimus 10Imatinib Mesylate 10Ifosfamide 10Filgrastim 10Radiation 9Bevacizumab 9Vincristine 8Carboplatin 8pazopanib 7Everolimus 7temsirolimus 6atezolizumab 6Peripheral Blood Stem Cell Transplantation 6Etoposide 6fludarabine phosphate 5Vorinostat 5Specimen Handling 5Radiotherapy, Conformal 5PM 01183 5Ipilimumab 5Erlotinib Hydrochloride 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × romidepsin × Sarcoma × Clear all
NCT00085540 2017-01-02

FR901228 in Treating Patients With Recurrent High-Grade Gliomas

National Cancer Institute (NCI)

Phase 1/2 Completed
50 enrolled 6 charts
CNSSarcoma

Astrocytoma, Brain Neoplasms, Glioblastoma, Oligodendroglioma, Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡